107 related articles for article (PubMed ID: 25376110)
21. Calcitonin doubling time in medullary thyroid carcinoma after the detection of distant metastases keenly predicts patients' carcinoma death.
Ito Y; Miyauchi A; Kihara M; Kudo T; Miya A
Endocr J; 2016 Jul; 63(7):663-7. PubMed ID: 27097545
[TBL] [Abstract][Full Text] [Related]
22. Calcitonin as Biomarker for the Medullary Thyroid Carcinoma.
Bae YJ; Schaab M; Kratzsch J
Recent Results Cancer Res; 2015; 204():117-37. PubMed ID: 26494386
[TBL] [Abstract][Full Text] [Related]
23. Utility of serum procalcitonin for screening and risk stratification of medullary thyroid cancer.
Machens A; Lorenz K; Dralle H
J Clin Endocrinol Metab; 2014 Aug; 99(8):2986-94. PubMed ID: 24840813
[TBL] [Abstract][Full Text] [Related]
24. Intraoperative high-dose calcium stimulation test in patients with sporadic medullary thyroid carcinoma is highly accurate in predicting lateral neck metastases.
De Crea C; Raffaelli M; Milano V; Carrozza C; Zuppi C; Bellantone R; Lombardi CP
Surgery; 2016 Jan; 159(1):70-6. PubMed ID: 26456123
[TBL] [Abstract][Full Text] [Related]
25. Implementing the Modified 2009 American Thyroid Association Risk Stratification System in Thyroid Cancer Patients with Low and Intermediate Risk of Recurrence.
Pitoia F; Jerkovich F; Urciuoli C; Schmidt A; Abelleira E; Bueno F; Cross G; Tuttle RM
Thyroid; 2015 Nov; 25(11):1235-42. PubMed ID: 26132983
[TBL] [Abstract][Full Text] [Related]
26. Should serum calcitonin be routinely measured in patients presenting with thyroid nodule?
Tormey WP; Byrne B; Hill AD; Sherlock M; Thompson CJ
Minerva Endocrinol; 2017 Dec; 42(4):306-310. PubMed ID: 28092147
[TBL] [Abstract][Full Text] [Related]
27. Changes in risk factors and Tumor Node Metastasis stage of sporadic medullary thyroid carcinoma over 41 years, before and after the routine measurements of serum calcitonin.
Karga H; Giagourta I; Papaioannou G; Doumouchtsis K; Polymeris A; Thanou S; Papamichael K; Zerva C
Metabolism; 2011 May; 60(5):604-8. PubMed ID: 20667564
[TBL] [Abstract][Full Text] [Related]
28. Lymph node metastases and elevated postoperative calcitonin: Predictors of poor survival in medullary thyroid carcinoma.
Siironen P; Hagström J; Mäenpää HO; Louhimo J; Arola J; Haglund C
Acta Oncol; 2016; 55(3):357-64. PubMed ID: 26339947
[TBL] [Abstract][Full Text] [Related]
29. Need for a revised staging consensus in medullary thyroid carcinoma.
Boostrom SY; Grant CS; Thompson GB; Farley DR; Richards ML; Hoskin TL; Hay ID
Arch Surg; 2009 Jul; 144(7):663-9. PubMed ID: 19620547
[TBL] [Abstract][Full Text] [Related]
30. Prognostic variables and calcitonin in medullary thyroid cancer.
Clark JR; Fridman TR; Odell MJ; Brierley J; Walfish PG; Freeman JL
Laryngoscope; 2005 Aug; 115(8):1445-50. PubMed ID: 16094121
[TBL] [Abstract][Full Text] [Related]
31. Is basal ultrasensitive measurement of calcitonin capable of substituting for the pentagastrin-stimulation test?
Pina G; Dubois S; Murat A; Berger N; Niccoli P; Peix JL; Cohen R; Guillausseau C; Charrie A; Chabre O; Cornu C; Borson-Chazot F; Rohmer V;
Clin Endocrinol (Oxf); 2013 Mar; 78(3):358-64. PubMed ID: 22913268
[TBL] [Abstract][Full Text] [Related]
32. Macrocalcitonin Is a Novel Pitfall in the Routine of Serum Calcitonin Immunoassay.
Alves TG; Kasamatsu TS; Yang JH; Meneghetti MC; Mendes A; Kunii IS; Lindsey SC; Camacho CP; Dias da Silva MR; Maciel RM; Vieira JG; Martins JR
J Clin Endocrinol Metab; 2016 Feb; 101(2):653-8. PubMed ID: 26647152
[TBL] [Abstract][Full Text] [Related]
33. Dynamic risk stratification in medullary thyroid carcinoma: Single institution experiences.
Choi JB; Lee SG; Kim MJ; Kim TH; Ban EJ; Lee CR; Lee J; Kang SW; Jeong JJ; Nam KH; Chung WY
Medicine (Baltimore); 2018 Jan; 97(3):e9686. PubMed ID: 29505021
[TBL] [Abstract][Full Text] [Related]
34. Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL).
Bethel MA; Patel RA; Thompson VP; Merrill P; Reed SD; Li Y; Ahmadi S; Katona BG; Gustavson SM; Ohman P; Iqbal N; Gagel RF; Hernandez AF; Buse JB; Holman RR;
Diabetes Care; 2019 Jun; 42(6):1075-1080. PubMed ID: 31010875
[TBL] [Abstract][Full Text] [Related]
35. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level.
Machens A; Schneyer U; Holzhausen HJ; Dralle H
J Clin Endocrinol Metab; 2005 Apr; 90(4):2029-34. PubMed ID: 15634717
[TBL] [Abstract][Full Text] [Related]
36. [The prognostic importance of calcitonin screening in familial medullary thyroid carcinoma].
Raue F; Geiger S; Buhr H; Frank-Raue K; Ziegler R
Dtsch Med Wochenschr; 1993 Jan; 118(3):49-52. PubMed ID: 8425457
[TBL] [Abstract][Full Text] [Related]
37. Calcitonin and procalcitonin in patients with medullary thyroid cancer or bacterial infection.
Kaczka K; Mikosiński S; Fendler W; Celnik A; Pomorski L
Adv Clin Exp Med; 2012; 21(2):169-78. PubMed ID: 23214280
[TBL] [Abstract][Full Text] [Related]
38. Biomarker-based risk stratification for previously untreated medullary thyroid cancer.
Machens A; Dralle H
J Clin Endocrinol Metab; 2010 Jun; 95(6):2655-63. PubMed ID: 20339026
[TBL] [Abstract][Full Text] [Related]
39. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
[TBL] [Abstract][Full Text] [Related]
40. A cut-off value of basal serum calcitonin for detecting macroscopic medullary thyroid carcinoma.
Kwon H; Kim WG; Choi YM; Jang EK; Jeon MJ; Song DE; Baek JH; Ryu JS; Hong SJ; Kim TY; Kim WB; Shong YK
Clin Endocrinol (Oxf); 2015 Apr; 82(4):598-603. PubMed ID: 25041034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
